Sight Sciences Announces Real-World 36-Month Study Confirming Long-Term Effectiveness of Standalone OMNI Surgical System in Managing Primary Open-Angle Glaucoma

GlobeNewswireJan 8 05:05

Earnings Call Summary | Sight Sciences(SGHT.US) Q3 2024 Earnings Conference

Futu NewsDec 30, 2024 20:12 · Conference Call

Lake Street Maintains Sight Sciences(SGHT.US) With Hold Rating, Maintains Target Price $5

Futu NewsDec 21, 2024 03:31 · Ratings

Lake Street Issues a Hold Rating on Sight Sciences (SGHT)

TipRanksDec 21, 2024 02:39 · Ratings

Sight Sciences Announces the Results of a Budget Impact Analysis for Its TearCare System for the Treatment of Meibomian Gland Disease ("MGD") Showing Cost Savings Over Existing Reimbursed Treatment Options

GlobeNewswireDec 20, 2024 05:05

Sight Sciences Is Maintained at Neutral by Citigroup

Dow JonesDec 12, 2024 03:32 · Ratings